AMPE Ampio Pharmaceuticals Inc.

0.47
0  0%
Previous Close 0.46
Open 0.47
Price To Book 11.64
Market Cap 73,928,430
Shares 158,780,993
Volume 751,045
Short Ratio 13.67
Av. Daily Volume 1,364,152
Stock charts supplied by TradingView

NewsSee all news

  1. Ampio Pharmaceutical's Application to the FDA for a Clinical Study of Ampion™ to Treat COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS) featured in FOX News (VIDEO)

    ENGLEWOOD, Colo., April 2, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a pre-revenue development stage biopharmaceutical company focused on the development of immunology based therapies to treat

  2. Ampio Suspends Patient Enrollment in its Phase 3 Study of Ampion for Severe Osteoarthritis of the Knee and Explores Other Options to Complete Trial

    ENGLEWOOD, Colo., March 24, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE, the ", Company", )), a pre-revenue development stage biopharmaceutical company announced today that it has suspended patient

  3. Ampio is Preparing an Expanded Access FDA protocol to Study Nebulized Ampion as a Treatment for Moderate to Severe Acute Respiratory Distress Syndrome Associated with COVID-19

    ENGLEWOOD, Colo., March 24, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a pre-revenue development stage biopharmaceutical company focused on the development of immunology based therapies to treat

  4. Ampio Provides Corporate Update

    ENGLEWOOD, Colo., Feb. 21, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment ("SPA") Phase III clinical trial

  5. Ampio Provides Update on AP-013 Phase III Clinical Trial and Annual Meeting Conference Call Number

    ENGLEWOOD, Colo., Dec. 4, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III clinical trial titled 

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 enrolment has been suspended - noted March 24, 2020.
Ampion
Osteoarthritis of the Knee
Phase 2b data released May 2015 did not meet endpoints
Optina
Diabetic Macula Edema

Latest News

  1. Ampio Pharmaceutical's Application to the FDA for a Clinical Study of Ampion™ to Treat COVID-19 Induced Acute Respiratory Distress Syndrome (ARDS) featured in FOX News (VIDEO)

    ENGLEWOOD, Colo., April 2, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a pre-revenue development stage biopharmaceutical company focused on the development of immunology based therapies to treat

  2. Ampio Suspends Patient Enrollment in its Phase 3 Study of Ampion for Severe Osteoarthritis of the Knee and Explores Other Options to Complete Trial

    ENGLEWOOD, Colo., March 24, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE, the ", Company", )), a pre-revenue development stage biopharmaceutical company announced today that it has suspended patient

  3. Ampio is Preparing an Expanded Access FDA protocol to Study Nebulized Ampion as a Treatment for Moderate to Severe Acute Respiratory Distress Syndrome Associated with COVID-19

    ENGLEWOOD, Colo., March 24, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE), a pre-revenue development stage biopharmaceutical company focused on the development of immunology based therapies to treat

  4. Ampio Provides Corporate Update

    ENGLEWOOD, Colo., Feb. 21, 2020 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment ("SPA") Phase III clinical trial

  5. Ampio Provides Update on AP-013 Phase III Clinical Trial and Annual Meeting Conference Call Number

    ENGLEWOOD, Colo., Dec. 4, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III clinical trial titled 

  6. Ampio Provides Update on Continued Progress of AP-013 Phase III Clinical Trial and Manufacturing Facility

    ENGLEWOOD, Colo., Oct. 10, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) Phase III clinical trial titled

  7. Ampio Retains Legal Counsel for Transaction Advisory Committee

    ENGLEWOOD, Colo., Sept. 18, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) a development stage biopharmaceutical company, executing a Special Protocol Assessment (SPA) phase three clinical trial titled 

  8. Ampio Pharmaceuticals Updates Progress of SPA Clinical Trial

    ENGLEWOOD, Colo., Sept. 17, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE:AMPE) today announced the progress to date in the Company's special protocol assessment (SPA) phase three clinical trial